All of that aside, there is an argument to double down here at this valuation, potentially giving a good net return ... Novo Nordisk's intricate strategy for obesity and diabetes medicine ...

orforglipron appears to be the favorite now as it’s a daily pill vs a weekly injection. Lilly’s oral drug only showed 7.9% weight loss at the highest dose in 40 weeks compared to Novo’s 15% ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...

Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over 60 ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen ... though Jorgensen had predicted a return to growth in its biggest market — the United States — in the second ...

To stay ahead, Novo Nordisk is pushing its semaglutide treatments into other areas of medicine. “Cardiologists started being interested in GLP-1s,” Jørgensen told Fast Company in 2023.

no more complicated than swallowing a pill, will be even more popular -- and help Novo Nordisk to continue dominating this market. On the other hand, BioPharmaDive notes that the pill Novo wants ...

Novo Nordisk ... of Medicine showed that people lost more weight using Wegovy competitor Zepbound, made by pharmaceutical company Eli Lilly. Eli Lilly funded the study. Novo Nordisk's share ...